These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6133298)

  • 21. [Tardive dyskinesia in patients with schizophrenia treated with olanzapine - results from a 20-month, prospective, open study under naturalistic conditions].
    Szafrański T
    Psychiatr Pol; 2014; 48(6):1155-65. PubMed ID: 25717485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and epidemiologic aspects of tardive dyskinesia.
    Baldessarini RJ
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):8-13. PubMed ID: 2858483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Informing patients about tardive dyskinesia: four-year follow up of a trial of patient education.
    Chaplin R; Timehin C
    Aust N Z J Psychiatry; 2002 Feb; 36(1):99-103. PubMed ID: 11929445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study.
    Tenback DE; van Harten PN; Slooff CJ; Belger MA; van Os J;
    J Clin Psychiatry; 2005 Sep; 66(9):1130-3. PubMed ID: 16187770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tardive dyskinesia in elderly psychiatric patients: a 5-year study.
    Yassa R; Nastase C; Dupont D; Thibeau M
    Am J Psychiatry; 1992 Sep; 149(9):1206-11. PubMed ID: 1354413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of severe and mild tardive dyskinesia: implications for etiology.
    Gardos G; Cole JO; Schniebolk S; Salomon M
    J Clin Psychiatry; 1987 Sep; 48(9):359-62. PubMed ID: 2887550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prevalence of akathisia in patients receiving stable doses of clozapine.
    Chengappa KN; Shelton MD; Baker RW; Schooler NR; Baird J; Delaney J
    J Clin Psychiatry; 1994 Apr; 55(4):142-5. PubMed ID: 7915271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The natural history of tardive dystonia. A long-term follow-up study of 107 cases.
    Kiriakakis V; Bhatia KP; Quinn NP; Marsden CD
    Brain; 1998 Nov; 121 ( Pt 11)():2053-66. PubMed ID: 9827766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ten-year outcome of tardive dyskinesia.
    Gardos G; Casey DE; Cole JO; Perenyi A; Kocsis E; Arato M; Samson JA; Conley C
    Am J Psychiatry; 1994 Jun; 151(6):836-41. PubMed ID: 7910437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tardive dystonia and severe tardive dyskinesia. A comparison of risk factors and prognosis.
    Giménez-Roldán S; Mateo D; Bartolomé P
    Acta Psychiatr Scand; 1985 May; 71(5):488-94. PubMed ID: 2861717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A therapeutic approach to tardive dyskinesia.
    Fahn S
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):19-24. PubMed ID: 2858474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tardive dyskinesia--reversible and persistent.
    Jeste DV; Potkin SG; Sinha S; Feder S; Wyatt RJ
    Arch Gen Psychiatry; 1979 May; 36(5):585-90. PubMed ID: 35116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
    Beasley CM; Dellva MA; Tamura RN; Morgenstern H; Glazer WM; Ferguson K; Tollefson GD
    Br J Psychiatry; 1999 Jan; 174():23-30. PubMed ID: 10211147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study.
    Tenback DE; van Harten PN; Slooff CJ; van Os J
    Am J Psychiatry; 2006 Aug; 163(8):1438-40. PubMed ID: 16877660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Tardive dyskinesia: pergolid, a possible therapeutic option].
    Diehl A; Braus DF; Büchel C; Krumm B; Medori R; Gattaz WF
    Psychiatr Prax; 2003 Sep; 30(6):333-7. PubMed ID: 12970819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
    Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH
    Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors for tardive dyskinesia according to primary psychiatric diagnosis.
    Wolf ME; DeWolfe AS; Mosnaim AD
    Hillside J Clin Psychiatry; 1987; 9(1):3-11. PubMed ID: 2888712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of neuroleptic-induced movement disorders: an 8-year follow-up study in chronic schizophrenia inpatients.
    Parksepp M; Ljubajev Ü; Täht K; Janno S
    Nord J Psychiatry; 2016 Oct; 70(7):498-502. PubMed ID: 27093226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study.
    Sachdev P
    Aust N Z J Psychiatry; 2004 Jun; 38(6):445-9. PubMed ID: 15209837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.